Search

Filters

Clear All
  • 12
  • 44
  • 538

Phase

  • 9
  • 14
  • 49
  • 8
  • 66
  • 3
  • 439
  • 519
  • 256
  • 591
  • 3
  • 594

Found 594 results for IU Health Enterprise System

A listing of IU Health Enterprise System medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Dissecting the Genetic and Environmental Contributions of Autoimmune Liver Disease: Genetic Repository of Autoimmune Liver Disease and Contributing Exposures (GRACE)Study

C
Craig Lammert, MD
All genders
What is the purpose of this study?The overall objective of this proposal is to conduct a systematic approach to dissect both genetic underpinnings and non-genetic factors in the development of adult autoimmune liver diseases including autoimmune hepatitis (AIH), overlap AIH with Primary Biliary Cirrhosis (AIH-PBC), overlap AIH with Primary Sclerosing …
Learn More

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

S
Sherif Farag, MD
All genders
Observational
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and otherdications.
Learn More

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

J
Jessica Parker Metter
18 years - 100 years
Female
Phase 3
Interventional
What is the purpose of this study?The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer …
Learn More

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

B
Brian Weiss
12 months - 30 years
All genders
Phase 1/2
Interventional
What is the purpose of this study?This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits ofgavivint in treating patients with solid tumors that has come back (recurrent) or does notd to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help …
Learn More
591 - 594 of 594